ClinicalTrials.Veeva

Menu

Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease

L

Luo Xinxin

Status

Not yet enrolling

Conditions

Alzheimer's Disease (AD)

Treatments

Procedure: Lymphaticovenous Anastomosis

Study type

Interventional

Funder types

Other

Identifiers

NCT06706947
SSYLL-KY-20241002

Details and patient eligibility

About

The aim of this clinical trial is to determine whether Lymphaticovenous Anastomosis can treat Alzheimer's disease,in AD patients aged 18-80.he main questions it aims to answer are:

  1. Can Lymphaticovenous Anastomosis improve cognitive function, daily living ability, mood, or sleep status in patients with Alzheimer's dementia, demonstrating good therapeutic efficacy?
  2. Does deep Lymphaticovenous Anastomosis lead to changes in peripheral blood biomarker levels, neuroinflammatory responses, and neuroimaging in patients with Alzheimer's dementia?

Enrollment

20 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. At least two deputy chief physicians or above, diagnosed with Alzheimer's dementia according to the DSM-5 diagnostic criteria;
  2. Age between 18-80 years old;
  3. The course of the disease is at least 1 year;
  4. MMSE score ≤ 24 points; MoCA score < 26
  5. Brain MRI shows hippocampal atrophy;
  6. Patients and their families agree to participate in this project for surgical treatment and sign an informed consent form.

Exclusion criteria

  1. Individuals with contraindications for Lymphaticovenous Anastomosis; those allergic to anesthetics and contrast agents (indocyanine green);
  2. Those unable to cooperate with cranial magnetic resonance imaging and scale testing;
  3. Patients simultaneously suffering from schizophrenia, depression, bipolar disorder;
  4. Patients with severe somatic diseases (such as cardiovascular, liver, kidney, gastrointestinal, etc.), infectious diseases, and immune system disorders;
  5. Individuals with serious neurological diseases (such as epilepsy, cerebrovascular diseases, etc.), other types of dementia, mental retardation;
  6. Pregnant or lactating women.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Lymphaticovenous Anastomosis
Experimental group
Treatment:
Procedure: Lymphaticovenous Anastomosis

Trial contacts and locations

1

Loading...

Central trial contact

Xinxin Luo

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems